

Personalised Cancer Medicine Flashcards 2022

Breast Cancer



Standard

Estrogen Receptor
Progesterone Receptor

HER2

Genetic platforms: Mammaprint,
Oncotype, Prosigna, or Endopredict*

BRCA 1 and BRCA 2**

PDL-1***

PIK3CA****

*in early luminal breast cancer with high risk of relapsing
**in advanced triple negative or luminal breast cancer
*** in advanced triple negative breast cancer
**** in advanced luminal breast cancer

Recommended

NGS*****

***** Approved in US as companion diagnostics of a PI3K inhibitor

Currently not recommended

ESR1

FGFR1

AKT1

PTEN

Liquid biopsy and circulating
cancer cells

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System

The **Recommended** category is based on current recommendations by EMEA and FDA

1. Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018 Jul;20(7):815-826. doi: 10.1007/s12094-017-1800-5.
2. Litton JK, Burstein HJ, Turner NC. Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e1-e7. doi: 10.1200/EDBK_237715.
3. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006A.pdf



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

